Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma

Acta Oncologica

Volumn 55, Issue 4, 2016, Pages 519-520

  Lee, Joycelyn J X ^a   Chan, Alexandre ^a,b   Tang, Tiffany ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CHLORAMBUCIL; ETHAMBUTOL; GEMCITABINE; ISONIAZID; OXALIPLATIN; PEMBROLIZUMAB; PREDNISOLONE; RIFAMPICIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUBERCULOSTATIC AGENT;

AGED; ANTIBIOTIC THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEVER; HOSPITAL ADMISSION; HUMAN; LEG SWELLING; LETTER; LUNG GRANULOMA; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM TUBERCULOSIS; NODULAR SCLEROSIS HODGKIN LYMPHOMA; NONHUMAN; PELVIS LYMPH NODE; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN NODULE; SPUTUM CULTURE; TREATMENT RESPONSE; VERY ELDERLY; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; HODGKIN DISEASE; ISOLATION AND PURIFICATION; LYMPH NODE; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; PATHOGENICITY; PATHOLOGY; TUBERCULOSIS; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITUBERCULAR AGENTS; HODGKIN DISEASE; HUMANS; LYMPH NODES; MALE; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; NEOPLASM RECURRENCE, LOCAL; PROGRAMMED CELL DEATH 1 RECEPTOR; TOMOGRAPHY, X-RAY COMPUTED; TUBERCULOSIS;

EID: 84984568954     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1125017     Document Type: Letter

References (6)

1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015; 372: 311-9.
2. Moskowitz CH, Ribrag V, Michot JM, Martinelli G, Zinzani PL, Gutierrez M, et al. PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). Blood 2014; 124: 21s (suppl; abstr 290)
3. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125: 3393-400.
4. Molnar EL, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci USA 2010; 107: 13402-7.
5. Tousif S, Singh Y, Prasad DVR, Sharma P, Van Kaer L, Das G. T Cells from Programmed Death-1 Deficient Mice Respond Poorly to Mycobacterium tuberculosis Infection. PLoS One 2011; 6: E19864 doi: 10.1371/journal.pone.0019864,
6. Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A. CD4 T Cells Promote Rather than Control Tuberculosis in the absence of PD-1 mediated inhibition. J Immunol 2011; 186: 1598-607.